This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Stocks With Key Insider Buying

Furiex Pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

A key insider has bought a huge amount of stock in drug development collaboration company Furiex Pharmaceuticals (FURX), whose product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Insiders are paying up to own shares here, with the stock up over 12% so far in 2011.

Furiex has a market cap of $159.97 million and an enterprise value of $101.92 million. The company's estimated growth rate for next year is pegged at 58.7%. This is a cash-rich company, with a total cash position on its balance sheet of $55.69 million and total debt of zero.

A beneficial owner and director just bought 264,070 shares, or $4.2 million worth of stock, at $15.32 to $16 per share.

>>11 Biotech Stocks Loved or Hated by Hedge Funds

From a technical standpoint, this stock is currently trading above its 50-day and 200-day moving averages, which is bullish. The stock is now approaching a major breakout if it can manage to sustain a move and close above overhead resistance at $16.87 and above Wednesday's high of $17.25 a share.

If you're bullish on this stock, I would look to get long once it breaks out and closes above $16.87 to $17.25 on heavy volume. Look for volume that's tracking in close to or above its three-month average action of 60,165 shares. If we see a high-volume move over those levels, then look for this stock to re-test its August high of $19.26.
2 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
FURX $0.00 0.00%
CLMT $3.98 -2.50%
EGHT $11.86 -0.17%
FLS $46.71 -2.70%
KO $44.97 0.29%


Chart of I:DJI
DOW 17,652.67 -98.24 -0.55%
S&P 500 2,047.71 -15.66 -0.76%
NASDAQ 4,720.15 -43.0740 -0.90%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs